<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>多家生物技术和制药公司在周四的盘后交易中出现显著涨幅，主要受到公司更新、临床里程碑和收购猜测的推动。</p>
<p>中国苏轩堂药业（SXTC）上涨 13.6%，至 1.42 美元，增加 0.17 美元，此前宣布启动其战略人工智能（AI）洞察计划。该计划旨在将基于 AI 的分析整合到产品组合规划和市场情报中，强化公司向数据驱动、创新驱动的现代中医企业转型的长期愿景。</p>
<p>Revolution Medicines, Inc.（RVMD）上涨 15.1%，至 123.65 美元，盘后上涨 16.26 美元。此次上涨是因为《金融时报》报道默克正在与该公司进行收购谈判。当天早些时候，Revolution Medicines 收盘上涨 5%，在公司宣布 FDA 授予其 RAS(ON) G12D 选择性抑制剂 zoldonrasib 突破性疗法认定后，涨势加速。该认定适用于治疗曾接受抗 PD-1/PD-L1 疗法和铂类化疗的 KRAS G12D 突变局部晚期或转移性非小细胞肺癌成年患者。</p>
<p>KalVista Pharmaceuticals, Inc.（KALV）上涨 14.0%，至 18.04 美元，增加 2.22 美元，此前报告了截至 2025 年 12 月 31 日的第四季度和全年未经审计的全球净产品收入初步结果。公司还强调了其他运营指标，激发了投资者的乐观情绪。</p>
<p>Zentalis Pharmaceuticals, Inc.（ZNTL）上涨 8.1%，至 3.07 美元，增加 0.23 美元，尽管周四没有新的消息。投资者可能仍在对公司 1 月 6 日的企业更新做出反应，该更新概述了关键里程碑和预计在 2026 年开发 azenosertib 的势头。</p>
<p>BriaCell Therapeutics Corp.（BCTX）上涨 7.3%，至 7.81 美元，增加 0.53 美元，截至东部时间晚上 7:49。此次上涨没有任何新的公司特定公告，表明是由动量驱动的交易活动。</p>
<p>Equillium, Inc.（EQ）上涨 4.4%，至 1.18 美元，盘后交易增加 0.05 美元。周四没有报告新的进展，但该股票仍吸引了适度的买入兴趣。</p>
<p>Sagimet Biosciences Inc.（SGMT）上涨 7.7%，至 6.00 美元，增加 0.43 美元，此前宣布计划在即将举行的第十届年度 MASH-TAG 会议上展示海报，地点在犹他州帕克城。该展示将重点介绍其脂肪酸合成酶（FASN）抑制剂 denifanstat 在 F3 和 qFibrosis 阶段 4 MASH 患者中的抗纤维化效果，来自于其 2b 期 FASCINATE-2 临床试验的观察结果。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

KalVista制药

SGMT

中国苏轩堂药业

RVMD

<p>几家生物科技公司在盘后交易中出现显著上涨，主要受到公司更新和收购猜测的推动。中国苏轩堂药业（SXTC）在推出人工智能计划后上涨了 13.6%。Revolution Medicines（RVMD）在有关于默克（Merck）收购谈判和其药物获得 FDA 突破性认证的报道后上涨了 15.1%。KalVista 制药（KALV）因其积极的收入结果上涨了 14%。其他 notable 的涨幅公司包括 Zentalis Pharmaceuticals（ZNTL）、BriaCell Therapeutics（BCTX）、Equillium（EQ）和 Sagimet Biosciences（SGMT），它们均在没有重大新公告的情况下实现了上涨</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Several biotechnology and pharmaceutical companies posted notable gains in Thursday's after-hours trading session, driven by corporate updates, clinical milestones, and acquisition speculation.</p>
<div class="lb-trans"><p>多家生物技术和制药公司在周四的盘后交易中出现显著涨幅，主要受到公司更新、临床里程碑和收购猜测的推动。</p>
</div><p>China SXT Pharmaceuticals, Inc. (SXTC) climbed 13.6% to $1.42, adding $0.17 after announcing the launch of its Strategic Artificial Intelligence (AI) Insights Initiative. The program is designed to integrate AI-driven analytics into product portfolio planning and market intelligence, reinforcing the company's long-term vision of evolving into a data-informed, innovation-driven modern traditional Chinese medicine (TCM) enterprise.</p>
<div class="lb-trans"><p>中国苏轩堂药业（SXTC）上涨 13.6%，至 1.42 美元，增加 0.17 美元，此前宣布启动其战略人工智能（AI）洞察计划。该计划旨在将基于 AI 的分析整合到产品组合规划和市场情报中，强化公司向数据驱动、创新驱动的现代中医企业转型的长期愿景。</p>
</div><p>Revolution Medicines, Inc. (RVMD) surged 15.1% to $123.65, gaining $16.26 after-hours. The rally followed a Financial Times report that Merck is in talks to acquire the company. Earlier in the day, Revolution Medicines closed 5% higher, and momentum accelerated after the company announced that the FDA granted Breakthrough Therapy Designation to zoldonrasib, its RAS(ON) G12D-selective inhibitor. The designation applies to the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic NSCLC who have previously received anti-PD-1/PD-L1 therapy and platinum-based chemotherapy.</p>
<div class="lb-trans"><p>Revolution Medicines, Inc.（RVMD）上涨 15.1%，至 123.65 美元，盘后上涨 16.26 美元。此次上涨是因为《金融时报》报道默克正在与该公司进行收购谈判。当天早些时候，Revolution Medicines 收盘上涨 5%，在公司宣布 FDA 授予其 RAS(ON) G12D 选择性抑制剂 zoldonrasib 突破性疗法认定后，涨势加速。该认定适用于治疗曾接受抗 PD-1/PD-L1 疗法和铂类化疗的 KRAS G12D 突变局部晚期或转移性非小细胞肺癌成年患者。</p>
</div><p>KalVista Pharmaceuticals, Inc. (KALV) advanced 14.0% to $18.04, up $2.22 after reporting preliminary unaudited global net product revenue results for the fourth quarter and full year ended December 31, 2025. The company also highlighted other operational indicators, fueling investor optimism.</p>
<div class="lb-trans"><p>KalVista Pharmaceuticals, Inc.（KALV）上涨 14.0%，至 18.04 美元，增加 2.22 美元，此前报告了截至 2025 年 12 月 31 日的第四季度和全年未经审计的全球净产品收入初步结果。公司还强调了其他运营指标，激发了投资者的乐观情绪。</p>
</div><p>Zentalis Pharmaceuticals, Inc. (ZNTL) rose 8.1% to $3.07, adding $0.23 despite no fresh news on Thursday. Investors may still be reacting to the company's January 6 corporate update, which outlined key milestones and expected momentum in the development of azenosertib heading into 2026.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals, Inc.（ZNTL）上涨 8.1%，至 3.07 美元，增加 0.23 美元，尽管周四没有新的消息。投资者可能仍在对公司 1 月 6 日的企业更新做出反应，该更新概述了关键里程碑和预计在 2026 年开发 azenosertib 的势头。</p>
</div><p>BriaCell Therapeutics Corp. (BCTX) gained 7.3% to $7.81, up $0.53 as of 7:49 PM EST. The move came without any new company-specific announcements, suggesting momentum-driven trading activity.</p>
<div class="lb-trans"><p>BriaCell Therapeutics Corp.（BCTX）上涨 7.3%，至 7.81 美元，增加 0.53 美元，截至东部时间晚上 7:49。此次上涨没有任何新的公司特定公告，表明是由动量驱动的交易活动。</p>
</div><p>Equillium, Inc. (EQ) added 4.4% to $1.18, a $0.05 increase in after-hours trading. No new developments were reported on Thursday, but the stock still attracted modest buying interest.</p>
<div class="lb-trans"><p>Equillium, Inc.（EQ）上涨 4.4%，至 1.18 美元，盘后交易增加 0.05 美元。周四没有报告新的进展，但该股票仍吸引了适度的买入兴趣。</p>
</div><p>Sagimet Biosciences Inc. (SGMT) rose 7.7% to $6.00, gaining $0.43 after announcing plans to present a poster at the upcoming 10th Annual MASH-TAG Conference in Park City, Utah. The presentation will highlight observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients from the Phase 2b FASCINATE-2 clinical trial of its fatty acid synthase (FASN) inhibitor, denifanstat.</p>
<div class="lb-trans"><p>Sagimet Biosciences Inc.（SGMT）上涨 7.7%，至 6.00 美元，增加 0.43 美元，此前宣布计划在即将举行的第十届年度 MASH-TAG 会议上展示海报，地点在犹他州帕克城。该展示将重点介绍其脂肪酸合成酶（FASN）抑制剂 denifanstat 在 F3 和 qFibrosis 阶段 4 MASH 患者中的抗纤维化效果，来自于其 2b 期 FASCINATE-2 临床试验的观察结果。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

盘后生物科技股上涨：Revolution Medicines 因与默克的交易谈判报道而大涨，中国苏轩堂药业、KalVista 制药、Sagimet Biosciences 也纷纷上涨